Regulatory Issues Affecting Tumor Vaccines

  • Mark O. Thornton
  • Alexandra S. Worobec
  • Keith Wonnacott
  • Raj K. Puri
Part of the Cancer Drug Discovery and Development book series (CDD&D)


The progress made over the last few decades in understanding the genetic and immunological aspects of cancer has led to the development of a large number and variety of immune-based approaches to combat the disease. Among the products developed, or under development, have been receptor-targeted monoclonal antibodies (e.g., trastuzumab, tositumomab), cytokines (e.g., interferon-α [IFN-α], interleukin-2), growth factors (e.g., granulocyte-macrophage colony-stimulating factor [GM-CSF], granulocyte colony-stimulating factor [G-CSF1, erythropoietin), and an amalgam of innovative products collectively referred to as tumor vaccines.


Dendritic Cell Tumor Antigen Minimal Residual Disease Cancer Vaccine Regulatory Issue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moingeon P. Cancer vaccines. Vaccine 2001; 19:1305–1326.PubMedCrossRefGoogle Scholar
  2. 2.
    Banchereau J, Steinman, RM. Dendritic cells and the control of immunity. Nature 1998; 392:245–252.PubMedCrossRefGoogle Scholar
  3. 3.
    Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med 2001; 7:761–765.PubMedCrossRefGoogle Scholar
  4. 4.
    Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL Jr, Mellor AL. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297:1867–1870.PubMedCrossRefGoogle Scholar
  5. 5.
    Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG. Altered peptide ligand vaccination with Flt-3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98:8809–8814.PubMedCrossRefGoogle Scholar
  6. 6.
    Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850–854.PubMedCrossRefGoogle Scholar
  7. 7.
    Boon T. Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res 1992; 58:177–210.PubMedCrossRefGoogle Scholar
  8. 8.
    Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W. Immunity to oncogenic proteins. Immunol Rev 1995; 145:33–59.PubMedCrossRefGoogle Scholar
  9. 9.
    Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998; 187:1163–1167.PubMedCrossRefGoogle Scholar
  10. 10.
    Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49:281–355.PubMedCrossRefGoogle Scholar
  11. 11.
    Pardoll DM. Cancer vaccines: a road map for the next decade. Curr Opin Immunol 1996; 8:619–621.PubMedCrossRefGoogle Scholar
  12. 12.
    Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002; 14:178–182.PubMedCrossRefGoogle Scholar
  13. 13.
    Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25:97–138.PubMedCrossRefGoogle Scholar
  14. 14.
    Okada N, Tsujino M, Hagiwara Y, Tada A, Tamura Y, Mori K, Saito T, Nakagawa S, Mayumi T, Fujita T, Yamamoto A. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 2001; 84:1564–1570.PubMedCrossRefGoogle Scholar
  15. 15.
    Fong L, Brockstedt D, Benike C, Wu L, Englemen EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001; 166:4254–4259.PubMedGoogle Scholar
  16. 16.
    Green S, Liu PY, O’Sullivan J. Factorial design considerations. J Clin Oncol 2002; 20:3424–3430.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Mark O. Thornton
  • Alexandra S. Worobec
  • Keith Wonnacott
  • Raj K. Puri

There are no affiliations available

Personalised recommendations